ATE461932T1 - Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors - Google Patents

Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors

Info

Publication number
ATE461932T1
ATE461932T1 AT05737774T AT05737774T ATE461932T1 AT E461932 T1 ATE461932 T1 AT E461932T1 AT 05737774 T AT05737774 T AT 05737774T AT 05737774 T AT05737774 T AT 05737774T AT E461932 T1 ATE461932 T1 AT E461932T1
Authority
AT
Austria
Prior art keywords
cupyrimidines
adenosine
antagonists
receptor
Prior art date
Application number
AT05737774T
Other languages
English (en)
Inventor
Bernard Neustadt
Jinsong Hao
Hong Liu
Craig Boyle
Samuel Chackalamannil
Unmesh Shah
Andrew Stamford
Joel Harris
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34966464&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE461932(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE461932T1 publication Critical patent/ATE461932T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT05737774T 2004-04-21 2005-04-19 Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors ATE461932T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56391304P 2004-04-21 2004-04-21
US60996604P 2004-09-15 2004-09-15
PCT/US2005/013454 WO2005103055A1 (en) 2004-04-21 2005-04-19 PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PYRIMIDINE ADENOSINE A2A RECEPTOR ANTAGONISTS

Publications (1)

Publication Number Publication Date
ATE461932T1 true ATE461932T1 (de) 2010-04-15

Family

ID=34966464

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05737774T ATE461932T1 (de) 2004-04-21 2005-04-19 Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors

Country Status (16)

Country Link
US (1) US7709492B2 (de)
EP (1) EP1745047B1 (de)
JP (2) JP2007533754A (de)
KR (1) KR20060135901A (de)
AR (1) AR048617A1 (de)
AT (1) ATE461932T1 (de)
AU (1) AU2005236059B2 (de)
CA (1) CA2563635A1 (de)
DE (1) DE602005020127D1 (de)
ES (1) ES2342082T3 (de)
IL (1) IL178674A0 (de)
MX (1) MXPA06012231A (de)
NZ (1) NZ550591A (de)
PE (1) PE20060185A1 (de)
TW (1) TW200538118A (de)
WO (1) WO2005103055A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60110219T2 (de) * 2000-05-26 2006-03-09 Schering Corp. Adenosin a2a rezeptor antagonisten
US20060128694A1 (en) * 2002-12-19 2006-06-15 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
WO2005042478A2 (en) 2003-09-19 2005-05-12 Janssen Pharmaceutica, N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
MY147518A (en) 2004-09-15 2012-12-31 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
JP2008523075A (ja) * 2004-12-13 2008-07-03 アリーナ ファーマシューティカルズ， インコーポレイテッド ５ｈｔ２ｃレセプター関連障害の処置に有用な５ｈｔ２ｃレセプターのモジュレーターとしてのｎ−ビアリールピペラジン誘導体およびｎ−アリールヘテロアリールピペラジン誘導体
TW200633721A (en) * 2004-12-14 2006-10-01 Shionogi & Co A pharmaceutical composition for treating constipation
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
EP1934227B1 (de) * 2005-09-19 2011-12-21 Schering Corporation 2-HETEROARYLPYRAZOLO[4,3-e]-1, 2, 4-TRIAZOLO-[1,5-c]-PYRIMIDINE ALS ANTAGONISTEN DES ADENOSIN-A2a-REZEPTORS
PE20070521A1 (es) 2005-09-23 2007-07-13 Schering Corp 7-[2-[4-(6-FLUORO-3-METIL-1,2-BENCISOXAZOL-5-IL)-1-PIPERAZINIL]ETIL]-2-(1-PROPINIL)-7H-PIRAZOL-[4,3-E]-[1,2,4]-TRIAZOL-[1,5-C]-PIRIMIDIN-5-AMINA COMO ANTAGONISTA DEL RECEPTOR DE ADENOSINA A2a
PE20080188A1 (es) 2006-04-18 2008-03-10 Janssen Pharmaceutica Nv Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol
US7723343B2 (en) 2007-03-30 2010-05-25 King Pharmaceuticals Research And Development, Inc. Adenosine A2A receptor antagonists
JP2011513417A (ja) 2008-03-04 2011-04-28 シェーリング コーポレイション アデノシンＡ２ａ受容体アンタゴニストとして使用するための１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オンおよびピラゾロ［４，３−ｅ］−１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オン化合物
WO2010068756A2 (en) 2008-12-10 2010-06-17 Thesis Chemistry, Llc Process for manufacture of optically active 2-(acyloxymethyl)-1, 3 oxathiolanes
US8273754B2 (en) * 2008-12-30 2012-09-25 Arqule, Inc. Substituted 1H-pyrazolo[3,4-D]pyrimidine-6-amine compounds
WO2010099518A2 (en) * 2009-02-27 2010-09-02 Thesis Chemistry, Llc Method for manufacture of 2-oxoimidazolidines
EP2406243B1 (de) 2009-03-10 2014-05-07 Takeda Pharmaceutical Company Limited Benzofuranderivate
US8343961B2 (en) * 2009-03-31 2013-01-01 Arqule, Inc. Substituted heterocyclic compounds
NZ599099A (en) * 2009-10-08 2013-05-31 Sanofi Sa Phenyloxadiazole derivatives as pgds inhibitors
AU2011306358B2 (en) * 2010-09-24 2014-08-14 Impetis Biosciences Ltd. Fused tricyclic compounds as adenosine receptor antagonist
WO2012135084A1 (en) * 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. METABOLITES OF 2-(FURAN-2-YL)-7-(2-(4-(4-(2-METHOXYETHOXY)PHENYL)PIPERAZIN-1-YL)ETHYL)-7H-PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-5-AMINE AND THEIR UTILITY AS ADENOSINE A2a RECEPTOR ANTAGONISTS
EP2797880B1 (de) * 2011-12-27 2017-03-01 Bio-Pharm Solutions Co., Ltd. Phenylcarbamatverbindungen zur vorbeugung oder behandlung von epilepsie
TWI801372B (zh) * 2017-03-30 2023-05-11 比利時商艾特歐斯比利時有限公司 作為a2a抑制劑的硫胺甲酸酯衍生物以及用於癌症治療的方法
AU2018246355B2 (en) * 2017-03-30 2021-12-09 iTeos Belgium SA 2-oxo-thiazole derivatives as A2A inhibitors and compounds for use in the treatment of cancers
CN108218796A (zh) * 2017-12-31 2018-06-29 佛山市赛维斯医药科技有限公司 含酰肼结构的化合物、制备方法及其用途
CN108191775A (zh) * 2017-12-31 2018-06-22 佛山市赛维斯医药科技有限公司 一种末端烯丙基丙酰肼结构化合物及其用途
CN108148004A (zh) * 2017-12-31 2018-06-12 佛山市赛维斯医药科技有限公司 一种含丙酰肼和嘧啶结构的化合物、制备方法及其用途
CN107935953A (zh) * 2017-12-31 2018-04-20 佛山市赛维斯医药科技有限公司 含末端烯键和酰肼结构的comt抑制剂、制备方法及其用途
EP3774813A4 (de) 2018-04-08 2021-11-17 BeiGene, Ltd. Pyrazolotriazolopyrimidinderivate als a2a-rezeptor-antagonist
CN110742893B (zh) * 2018-07-23 2024-04-05 百济神州(北京)生物科技有限公司 A2a受体拮抗剂治疗癌症的方法
BE1026758B1 (fr) * 2018-09-11 2020-06-09 Iteos Therapeutics S A Composition pharmaceutique comprenant des dérivés de thiocarbamate inhibiteurs d’a2a
BE1026615B1 (fr) * 2018-09-27 2020-07-06 Iteos Therapeutics S A Combinaison d’un inhibiteur du récepteur a2a et d'un agent anticancéreux
US11376255B2 (en) 2018-09-11 2022-07-05 iTeos Belgium SA Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents
AU2019337974A1 (en) * 2018-09-11 2021-04-08 iTeos Belgium SA Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents
US11427594B2 (en) 2018-09-27 2022-08-30 iTeos Belgium SA Non brain penetrant A2A inhibitors and methods for use in the treatment of cancers
BE1026602B1 (fr) * 2018-09-27 2020-06-18 Iteos Therapeutics S A Inhibiteurs d’a2a ne penetrant pas dans le cerveau et methodes d’utilisation dans le traitement de cancers
US12414952B2 (en) 2018-11-20 2025-09-16 Merck Sharp & Dohme Llc Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
AU2019383948A1 (en) 2018-11-20 2021-05-20 Merck Sharp & Dohme Llc Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
AU2019388872A1 (en) 2018-11-30 2021-05-27 Merck Sharp & Dohme Llc 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
WO2020112700A1 (en) 2018-11-30 2020-06-04 Merck Sharp & Dohme Corp. 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
WO2020227156A1 (en) * 2019-05-03 2020-11-12 Nektar Therapeutics Adenosine 2 receptor antagonists
JP2022540583A (ja) * 2019-07-17 2022-09-16 テオン セラピューティクス，インク． アデノシンａ２ａ受容体アンタゴニスト及びその使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
WO1995003806A1 (en) * 1993-07-27 1995-02-09 Kyowa Hakko Kogyo Co., Ltd. Remedy for parkinson's disease
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
DE60110219T2 (de) * 2000-05-26 2006-03-09 Schering Corp. Adenosin a2a rezeptor antagonisten
GB0100624D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
KR100687954B1 (ko) 2001-10-15 2007-02-27 쉐링 코포레이션 아데노신 Ａ2ａ 수용체 길항제로서의이미다조（4,3-ｅ）-1,2,4-트리아졸로（1,5-ｃ） 피리미딘
TWI331036B (en) 2002-12-19 2010-10-01 Schering Corp Adenosine a2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
EP1622912B1 (de) * 2003-04-23 2009-05-27 Schering Corporation 2-alkinyl- und 2-alkenyl-pyrazolo-[4,3-e] -1,2,4-triazolo-[1,5-c] -pyrimidinadenosin a2a rezeptorantagonisten

Also Published As

Publication number Publication date
TW200538118A (en) 2005-12-01
HK1095818A1 (en) 2007-05-18
AR048617A1 (es) 2006-05-10
KR20060135901A (ko) 2006-12-29
EP1745047A1 (de) 2007-01-24
JP2007533754A (ja) 2007-11-22
CA2563635A1 (en) 2005-11-03
JP2008231111A (ja) 2008-10-02
ES2342082T3 (es) 2010-07-01
DE602005020127D1 (de) 2010-05-06
NZ550591A (en) 2010-10-29
WO2005103055A1 (en) 2005-11-03
US20050239795A1 (en) 2005-10-27
MXPA06012231A (es) 2006-12-15
EP1745047B1 (de) 2010-03-24
IL178674A0 (en) 2007-02-11
AU2005236059A1 (en) 2005-11-03
AU2005236059B2 (en) 2009-01-15
PE20060185A1 (es) 2006-03-20
US7709492B2 (en) 2010-05-04

Similar Documents

Publication Publication Date Title
ATE461932T1 (de) Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors
SMAP200600024A (it) 2,6-Biseteroaril-4-amminopirimidine come antagonisti del recettore dell'adenosia
ATE505467T1 (de) 2-aza-bicycloä3.1.0ühexanderivate als orexin- rezeptorantagonisten
NL1032713A1 (nl) Histamine-3-receptorantagonisten.
ATE481404T1 (de) Adenosinderivate als agonisten am a2a-rezeptor
ATE384053T1 (de) Triazolderivate als tachykininrezeptor- antagonisten
ZA200800353B (en) Pyrazine derivatives useful as adenosine receptor antagonists
PT2570128T (pt) Antagonistas do receptor muscarínico de acetilcolina
ATE432282T1 (de) 2-alkinyl- und 2-alkenyl-pyrazolo-ä4,3-eü -1,2,4- triazolo-ä1,5-cü -pyrimidinadenosin a2a rezeptorantagonisten
DK1824856T3 (da) 2,4 (4,6)-pyrimidinderivater
DE60209251D1 (de) Adenosine a2a receptor antagonisten
DK1682142T3 (da) M3-muscarin-acetylcholin-receptor-antagonister
ZA200800320B (en) Indol-3-carbonyl-spiro-piperidine derivatives as Via receptor antagonists
IL186188A0 (en) Pyrimidindione derivatives as prokineticin 2 receptor antagonists
ATE458740T1 (de) 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten
EP1871752A4 (de) Antagonisten des amidopropoxyphenylorexinrezeptors
DE602006003628D1 (de) Purinderivate als a2a-rezeptoragonisten
ATE518834T1 (de) 2,3,4,9-tetrahydro-1h-carbazol-derivative als crth2-rezeptorantagonisten
DK1711465T3 (da) Hydroisoindolin-tachykinikreceptorantagonister
ATE538123T1 (de) 2-heteroarylpyrazoloä4,3-eü-1, 2, 4-triazolo-ä1,5-cü-pyrimidine als antagonisten des adenosin-a2a- rezeptors
DE60333866D1 (de) 2-aminocarbonlyl-chinolin-verbindungen als adenosin diphosphat plättchenrezeptor antagonisten
DK1973886T3 (da) Prokineticin-1-receptor-antagonister
DE60316411D1 (de) Thiazolderivate als npy-rezeptorantagonisten
ATE429428T1 (de) Indanderivate als antagonisten des mch-rezeptors
DE60305026D1 (de) 3,4-dihydrochinolin-2(1h)-on verbindungen als nr2b rezeptor antagonisten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties